A Phase I/II Study of Midostaurin (PKC412) and 5-Azacitidine for Elderly Patients With Acute Myelogenous Leukemia.

Trial Profile

A Phase I/II Study of Midostaurin (PKC412) and 5-Azacitidine for Elderly Patients With Acute Myelogenous Leukemia.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Jun 2016

At a glance

  • Drugs Azacitidine (Primary) ; Midostaurin (Primary)
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Haematological malignancies; Lymphoid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Jun 2016 Status changed from recruiting to active, no longer recruiting.
    • 04 Mar 2016 Planned primary completion date changed from 1 Dec 2013 to 1 Jun 2016 according to the ClinicalTrails.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top